Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. 1990

J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
Immunosciences Research and Computer Assisted Molecular Design Areas, Abbott Laboratories, Illinois 60064.

An evaluation of the quantitative structure-activity relationships (QSAR) for more than 100 hydroxamic acids revealed that the primary physicochemical feature influencing the in vitro 5-lipoxygenase inhibitory potencies of these compounds is the hydrophobicity of the molecule. A significant correlation was observed between the octanol-water partition coefficient of the substituent attached to the carbonyl of the hydroxamate and in vitro inhibitory activity. This correlation held for hydroxamic acids of diverse structure and with potencies spanning 4 orders of magnitude. Although the hydrophobicity may be packaged in a variety of structural ways and still correlate with potency, the QSAR study revealed two major exceptions. Specifically, the hydrophobicity of portions of compounds in the immediate vicinity of the hydroxamic acid functionality does not appear to contribute to increased inhibition and the hydrophobicity of fragments beyond approximately 12 A from the hydroxamate do not influence potency. The QSAR study also demonstrated that inhibitory activity was enhanced when there was an alkyl group on the hydroxamate nitrogen, when electron-withdrawing substituents were present and when the hydroxamate was conjugated to an aromatic system. These observations provide a simple description of the lipoxygenase-hydroxamic acid binding site.

UI MeSH Term Description Entries
D006877 Hydroxamic Acids A class of weak acids with the general formula R-CONHOH. Hydroxamic Acid,Acid, Hydroxamic,Acids, Hydroxamic
D001091 Arachidonate Lipoxygenases Enzymes catalyzing the oxidation of arachidonic acid to hydroperoxyarachidonates. These products are then rapidly converted by a peroxidase to hydroxyeicosatetraenoic acids. The positional specificity of the enzyme reaction varies from tissue to tissue. The final lipoxygenase pathway leads to the leukotrienes. EC 1.13.11.- . Arachidonic Acid Lipoxygenase,Lipoxygenase, Arachidonic Acid,Lipoxygenases, Arachidonate
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016859 Lipoxygenase Inhibitors Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. 5-Lipoxygenase Inhibitor,Lipoxygenase Inhibitor,12-Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors,Arachidonate 12-Lipoxygenase Inhibitors,Arachidonate 15-Lipoxygenase Inhibitors,Arachidonate 5-Lipoxygenase Inhibitors,Inhibitors, Lipoxygenase,12 Lipoxygenase Inhibitors,12-Lipoxygenase Inhibitors, Arachidonate,15 Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors, Arachidonate,5 Lipoxygenase Inhibitor,5 Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors, Arachidonate,Arachidonate 12 Lipoxygenase Inhibitors,Arachidonate 15 Lipoxygenase Inhibitors,Arachidonate 5 Lipoxygenase Inhibitors,Inhibitor, 5-Lipoxygenase,Inhibitor, Lipoxygenase,Inhibitors, 12-Lipoxygenase,Inhibitors, 15-Lipoxygenase,Inhibitors, 5-Lipoxygenase,Inhibitors, Arachidonate 12-Lipoxygenase,Inhibitors, Arachidonate 15-Lipoxygenase,Inhibitors, Arachidonate 5-Lipoxygenase

Related Publications

J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
December 2020, Journal of enzyme inhibition and medicinal chemistry,
J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
March 1987, Journal of medicinal chemistry,
J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
March 1994, Journal of pharmaceutical sciences,
J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
June 1997, Journal of medicinal chemistry,
J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
August 2003, Mini reviews in medicinal chemistry,
J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
June 1998, Chemical & pharmaceutical bulletin,
J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
November 1987, Journal of medicinal chemistry,
J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
January 1990, Journal of enzyme inhibition,
J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
April 1999, Bioorganic & medicinal chemistry letters,
J B Summers, and K H Kim, and H Mazdiyasni, and J H Holms, and J D Ratajczyk, and A O Stewart, and R D Dyer, and G W Carter
May 2006, Medicinal chemistry (Shariqah (United Arab Emirates)),
Copied contents to your clipboard!